ADVFN - Advanced Financial Network.
HOME» NASDAQ » T » TEVA Stock Price » TEVA Stock News

Teva Pharmaceutical Share News

 Teva Pharmaceutical Industries Limited (mm) Stock Price
TEVA Stock Price
 Teva Pharmaceutical Industries Limited (mm) Stock Chart
TEVA Stock Chart
 Teva Pharmaceutical Industries Limited (mm) Stock News
TEVA Stock News
 Teva Pharmaceutical Industries Limited (mm) Company Information
TEVA Company Information
 Teva Pharmaceutical Industries Limited (mm) Stock Trades
TEVA Stock Trades

US Court Rules For AstraZeneca's Seroquel XR Patent

DOW JONES NEWSWIRES A U.S. district court found the formulation patent for AstraZeneca PLC's (AZN, AZN.LN) top-selling antipsychotic drug Seroquel XR was valid, the pharmaceutical company said Thursday, offering it ammunition in its fight against generic versions of the drug. The U.S. District Court for New Jersey also found Par Pharmaceutical Cos.'s (PRX) Anchen Pharmaceuticals, Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Ltd. (500420.BY) and Mylan Pharmaceuticals Inc. had infringed the drug's extended-release formulation patent, which expires in 2017, AstraZeneca said. The ruling comes after the U.K.'s second-biggest drug company failed this month to prevent the U.S. Food and Drug Administration from giving final marketing approval to generic forms of Seroquel. A federal judge Friday refused to grant AstraZeneca an injunction against the FDA, ruling that the company had failed to make a clear case that it was entitled to one. AstraZeneca faces one of the highest exposures to drug-patent expirations within the pharmaceuticals sector. Seroquel, AstraZeneca's second best-selling product, generated $5.83 billion in revenue last year for the company and is the first of its best-selling drugs to lose U.S. patent protection. A U.K. court ruled against AstraZeneca's formulation patent following challenges from companies such as Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV). AstraZeneca's American depositary shares Thursday closed at $44.50 and were inactive after-hours. -By Drew FitzGerald, Dow Jones Newswires; 212-416-2909; Andrew.FitzGerald@dowjones.com

Stock News for Teva Pharmaceutical (TEVA)
DateTimeHeadline
03/30/201508:14:08Teva to Acquire Auspex in $3.2 Billion Deal
03/23/201509:59:36Teva Migraine Therapy Shows Positive Results in Phase IIb Study
03/02/201509:50:38Correction to Story About Teva Selling Pennsylvania Facility
03/02/201509:18:27Teva Sells Pennsylvania Facility to G&W Laboratories
02/17/201508:33:57Teva to Distribute Eagle Pharmaceutical's Cancer Drug in U.S.
01/26/201508:10:04FDA Rejects Antares' Application for Generic Migraine Drug

Teva Pharmaceutical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad